信迪利单抗联合化疗一线治疗晚期食管癌完全缓解一例
侯新芳;李帅;吴晨;任军芳;张鑫鑫;
摘要(Abstract)：
<正>食管癌是我国发病率第6位和死亡率第4位的恶性肿瘤[1]。我国食管癌发病率与死亡率均高于世界平均水平[2]。病理分型上,我国86.3%的食管癌病例属鳞癌[3]。长期以来化疗是转移性食管鳞癌的标准治疗方案,但对患者生存期延长有限。近年来,免疫检查点抑制剂已在食管癌二线及以上治疗中获得临床指南推荐[4]。2020年9月欧洲肿瘤内科学会(European Society for Medical Oncology, ESMO)年会公布的KEYNOTE-590研究结果显示帕博立珠单抗联合化疗一线治疗晚期食
关键词(KeyWords)： 食管癌;免疫治疗;免疫检查点抑制剂;免疫-化疗联合治疗;完全缓解
基金项目(Foundation):
作者(Authors): 侯新芳;李帅;吴晨;任军芳;张鑫鑫;
DOI: 10.13267/j.cnki.syzlzz.2021.014
参考文献(References)：
- [1]赵学科,雷玲玲,徐瑞华,等.食管鳞癌并发结直肠腺癌73例临床病理特征[J].实用肿瘤杂志, 2020,35(5):396-401.
- [2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].Ca-Cancer J Clin, 2018, 68(6):394-424.
- [3]陈茹,郑荣寿,张思维,等.2015年中国食管癌发病和死亡情况分析[J].中华预防医学杂志, 2019,53(11):1094-1097.
- [4] Yamamoto S, Kato K. Immuno-oncology for esophageal cancer[J]. Future Oncol, 2020, 16(32):2673-2681.
- [5] Kato JS, Shah MA. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer:the phase 3 KEYNOTE-590study[J]. Ann Oncol, 2020, 31(Suppl 4):LBA8.
- [6]宋昕,韩文莉,王盼盼,等.食管鳞癌、贲门腺癌和结肠腺癌高频突变基因谱比较[J].实用肿瘤杂志,2020, 35(5):401-407.
- [7]国家卫生健康委员会.食管癌诊疗规范(2018年版)[J].中华消化病与影像杂志:电子版, 2019,9(4):158-192.
- [8] Ajani JA, D'Amico TA, Bentrem DJ, et al. NCCN Clinical Practice Guidelines in oncology-esophageal and esophagogastric junction cancers(2020 version 5)[EB/OL].(2020-12-23)[2020-12-27]. http://www.nccn.org.
- [9]郝捷,李进,马军,等.中国临床肿瘤学会(CSCO)食管癌诊疗指南2020[M].北京:人民卫生出版社,2020:72.
- [10] Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition[J]. N Engl J Med, 2017,377(25):2500.
- [11] Chen J, Luo S, Qin S, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma(AC)or squamous cell carcinoma(SCC)of the esophagus as second-line therapy:Analysis of the Chinese subgroup in KEYNOTE-181[J]. Ann Oncol, 2019, 30(Suppl 5):mdz247. 086.